RaviKAmaravadiMD

PubMed

• Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti-PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival.
  Kevin L Ma, Tara C Mitchell, Meaghan Dougher, Cimarron E Sharon, Gabriella N Tortorello
  Clinical Cancer Research. 2024-11-01
• Divergent effects of acute and chronic PPT1 inhibition in melanoma.
  Mary Ann S Crissey, Amanda Versace, Monika Bhardwaj, Vaibhav Jain, Shujing Liu
  Autophagy. 2024-09-19
• 3 citations
  Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8T cells.
  Kevin Wang, Paulina Coutifaris, David Brocks, Guanning Wang, Tarek Azar
  Cancer Cell. 2024-09-09

Journal Articles

• Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers  
  Matthew C Hyman, Ian Frank, Scott E Hensley, Saar Gill, Dan T Vogl, Ivan Maillard, Daria V Babushok, Alexander C Huang, Sunita D Nasta, Jennifer C Walsh, Michael C Mil..., JAMA Internal Medicine
• Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-cell Populations  
  Zeynep Eroglu, Iman Osman, Theodore S Nowicki, Antoni Ribas, Michael A Davies, Farbod Darvishian, Daniel Y Wang, Douglas B Johnson, Ravi K Amaravadi, Clinical Cancer Research
• Autophagy in malignant transformation and cancer progression  
  Galluzzi L, Pietrocola1 F, Bravo-San Pedro JM, Amaravadi RK, Cecconi F, Codogno P, Debnath J, Karantza V, Kumar S, Levine B, Maiuri MC, Martin S, Penninger J, Piacen..., EMBO J, 1/1/2015
• Emerging Strategies to effectively target autophagy in cancer  
  Rebecca VW, Amaravadi RK, Oncogene, 1/1/2015
• Identification of secreted proteins that reflect autophagy dynamics with tumor cells  
  Krayya A, Piao S, Xu G, Zhang G, Gimotty PG, Xu X, Amaravadi RK, Speicher DW, Autophagy, 1/1/2015
• Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors  
  Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, ..., Clinical Cancer Research, 1/1/2015
• Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers  
  Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher M, Chen H, Sehgal C, O'Dwyer PJ, Oncologist, 1/1/2015
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer  
  Twyman-Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, Xu B, Dada H, Odiorizzi P, Herati R, Mansfield K, Patsch D, Amaravadi RK, Schuchter LM, Ishwa..., Nature, 1/1/2015
• Targeting the lysosome in cancer  
  Piao S, Amaravadi RK, Ann Ny Acad Sci, 1/1/2015
• BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth  
  Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis GC, Gangadhar TC, Schuchter LM, Li..., Clin Cancer Res, 1/1/2015
• Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression  
  Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB, European Journal of Cancer, 1/1/2015
• Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma  
  Xu MJ, Dorsey JF, Amaravadi R, Karakousis G, Simone CB 2nd, Xu X, Xu W, Carpenter EL, Schuchter L, Kao GD, Oncologist, 1/1/2015
• miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment  
  Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Xu W, Wei Z, Herlyn M, Yao Y, Zhang L, ..., Pigment Cell and Melanoma Research, 1/1/2015
• A Phase 1 Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma  
  Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA., Molecular Cancer Therapeutics, 1/1/2015
• Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma  
  Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, Amavaradi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KS., Pigement Cell and Melanoma Research, 1/1/2014
• Phase I and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in dogs with spontaneously occurring lymphoma  
  Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH, Autophagy, 1/1/2014
• Combined Inhibition of Autophagy and HDAC inhibition: A Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Analysis of Hydroxychloroquine in Combination...  
  Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi R, Davis LE, Mita A, Curiel TJ, Espitia CM, Nawrocki ST, Giles FJ, Carew JS., Autophagy, 1/1/2014
• A Phase I/II Trial of Hydroxychloroquine in Conjunction with RadiationTherapy and Concurrent and Adjuvant Temozolomide in Patients with NewlyDiagnosed Glioblastoma Mul...  
  Myrna R. Rosenfeld, Jeffrey G. Supko, Stuart A. Grossman, Steven Brem, Tom Mikkelson, Daniel Wang, Claire Chang, Janice Hu, Quentin McAfee, Andrea Troxel, Shengfu Pia..., Autophagy, 1/1/2014
• Combined autophagy and proteasome inhibition: Phase I trial of hydroxychloroquine with bortezomib in patients with relapsed refractory multiple myeloma  
  Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, Paul TM, Nichols CW, Porter DL, Kaplan J, Mallon G, Bradner ..., Autophagy, 1/1/2014
• Autophagy Gene Atg16l1 Prevents Lethal T CellAlloreactivity Mediated by Dendritic Cells  
  Hubbard-Lucey V, Shono Y,Maurer K,West ML,Singer NV,Ziegler CG, Lezcano, C, Motta AC,Schmid K,Levi SM,Murphy GF,Liu C,Winkler JD,Amaravadi JK,Rogler G,Dickinson AM,Hol..., Immunity, 1/1/2014
• Targeting ER stress induced-autophagy overcomes resistance to BRAF inhibition in melanoma  
  Ma XH, Piao SF, Dey S, Mcafee Q, Karakousis G, Villaneuva J , Hart LS, Levi S, Hu J, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M,..., Journal of Clinical Investigation, 1/1/2014
• Ocular Toxicity in BRAF Mutant Melanoma Patients Treated With Vemurafenib  
  Choe, C, Mcarthur GA, Yang M, Caro I, Kempen JH, Amaravadi RK, Am J Ophthalmology, 1/1/2014
• Autophagy: a targetable linchpin of cancer cell metabolism  
  Robert Leone, Ravi Amaravadi, Trends in Endocrinology and Metabolism Cell Press, 1/24/2013
• Upregulation of ERBB3 by FOXD3, an adaptive response to RAF and MEK inhibitors  
  Abel EV, Basile KJ, Kugel CH, Witkiewicz AK, Le K, Amaravadi RK, Karakousis GC, Xu X, Wei Xu W, Schuchter LM, Lee JB, Ertel A,Fortina P, Aplin AE., Journal of Clinical Investigation, 1/1/2013
• Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma  
  Villanueva. J., Infante, J.R., Krepler, C., Reyes-Uribe, P., Samanta, M., Chen, H-Y., Li, B., Swoboda, R., Wilson, M., Vultur,A., Fukunaba-Kalabis, M., Wubbenhorst, B..., Cell Reports, 1/1/2013
• Join now to see all

Books/Book Chapters

• Lysosomes, basic mechanisms and roles in disease and drug development. 
  Chapter: Targeting autophagy in cancer therapy. 
  Willis FBEditors: Xiaohong Ma, Shengfu Piao, Quentin Mcafee, Ravi Amaravadi.John Wiley and Sons2014
• Cell Death Signaling in Cancer Biology 
  Chapter: The role of autophagy in drug resistance and potential for therapeutic targeting. Chapter 14 
  Page 87 - 116Editors: Rangwala R, Amaravadi RK.Springer2013

Abstracts/Posters

• Mouse models address key concerns about autophagy inhibition for cancer therapy.
  Amaravadi RK, Debnath J, Cancer Discovery, 1/1/2014
• PUMA: a puzzle piece in chloroquine's antimelanoma activity.
  Amaravadi RK, Journal of Investigative Dermatology, 1/1/2013
• Efficacy, Safety and Pharmacokinetics of a new formulation of the BRAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib from Part D of a Phase ...
  R. Amaravadi, R. Kudchadkar, R. Gonzalez, D. Lawrence, J. Sosman, J.R. Infante, A. Daud, R. F. Kefford, J. Cebon, W. Sharfman, L. Schuchter, P. Boasberg, K. Lewis, K...., J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2013
• Clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) and irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer: Phase 2 results
  N. Senzer, P. LoRusso, L. Martin, R. Schilder, R. Amaravadi, K. Papadopoulos, E. Segota, D. Weng, M. Graham, A. Adjei, J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2013
• Gamma knife stereotactic radio-surgery and BRAF inhibition in metastatic melanoma
  Melissa Wilson, John Y Lee, Michelle Alonso-Basanta, Wei Xu, Suzanne McGettigan, Lynn Mara Schuchter, Ravi K. Amaravadi, Tara C. Gangadhar, J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2013
• NRAS and BRAF mutations in atypical melanocytic lesions arising in melanoma patients treated with vemurafenib.
  Emily Y. Chu, Melissa Wilson, Joseph Sobanko, Christopher Miller, EunRan Suh, Wei Xu, Richard Letrero, Rosalie Elenitsas, Giorgos Karakousis, Xiao wei Xu, David Elder,..., J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2013
• Autophagy and tumor cell invasion.
  Amaravadi RK, Cell Cycle, 1/14/2012
• Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens.
  Gerald J. Fetterly, Biao Liu, Neil N. Senzer, Ravi K. Amaravadi, Russell J. Schilder, Lainie P. Martin, Patricia LoRusso, Kyriakos P. Papadopoulos, Alex A. Adjei, Patr..., J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2012
• Guidelines for the use and interpretation of assays for monitoring autophagy.
  Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S..., Autophagy, 1/1/2012
• Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with docetaxel.
  Muralidhar Beeram, Amita Patnaik, Ravi K. Amaravadi, Naomi B. Haas, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Lon S. Smith, Kathleen Harlacker, Guillermo Espino, M..., J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2012
• MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with docetaxel.
  Muralidhar Beeram, Amita Patnaik, Ravi K. Amaravadi, Naomi B. Haas, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Lon S. Smith, Kathleen Harlacker, Guillermo Espino, M..., J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2012
• Lys05: a new lysosomal autophagy inhibitor.
  Amaravadi RK, Winkler JD, Autophagy, 1/1/2012
• Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM).
  K. B. Kim, K. T. Flaherty, P. B. Chapman, J. A. Sosman, A. Ribas, G. A. McArthur, R. K. Amaravadi, R. J. Lee, K. B. Nolop, I. Puzanov, Journal of Clinical Oncology, 1/29/2011
• A phase 0 exploratory study to assess the pharmacodynamic effects of single intratumoral dose of a novel bispecific targeting/immune-activating agent on the melanoma t...
  L. A. Fecher, Y. McGrath, D. D. Williams, N. J. Hassan, M. Kalos, L. M. Schuchter, R. K. Amaravadi, A. Chew, E. A. Veloso, B. J. Czerniecki, G. Karakousis, G. P. Linet..., Journal of Clinical Oncology, 1/29/2011
• Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.
  W. H. Sharfman, F. S. Hodi, D. P. Lawrence, K. T. Flaherty, R. K. Amaravadi, K. B. Kim, R. Dummer, S. Gobbi, I. Puzanov, J. A. Sosman, K. Dohoney, L. P. Lam, S. Kakar,..., Journal of Clinical Oncology, 1/29/2011
• Cancer. Autophagy in tumor immunity.
  Amaravadi, Ravi K, Science, 1/16/2011
• Phase 1 study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors and lymphoma to evaluate safety, pharmacokinetics, pharmacodynamics, and antitum...
  Ravi K. Amaravadi, Russell J. Schilder, Grace K. Dy, Wen W. Ma, Gerald J. Fetterly Jr., David E. Weng, Martin A. Graham, Jennifer M. Burns, Srinivas K. Chunduru, Steph..., Proceedings of AACR, 1/1/2011
• Therapeutic modulation of autophagy overcomes resistance to BRAF inhibition in BRAF mutant melanoma
  Ma XH, Piao S, Villanueva J, Karakousis G, Shuchter L, Lynch J, Herlyn M, Davies M, Amaravadi RK, Society for Melanoma Research annual meeting, 1/1/2011
• Combined mTOR inhibition and autophagy inhibition: Phase I trial of temsirolimus and hydroxychloroquine in patients with advanced solid tumors (dose escalation) and me...
  Amaravadi RK, Rangwala R, MCafee QM, Fecher L, Chang C, Torigian D, Alavi A, Saboury B, Panosian J, O'Dwyer, PJ, Schuchter, LM, Society for Melanoma Research annual meeting, 1/1/2011
• Prolonged responses to vemurafenib in patients with BRAFV600 mutant melanoma with low tumor burden at baseline.
  Amaravadi R, Kim K, Flaherty K, Chapman P, Puzanov I, Sosman J, Ribas A, Lee R, Nolop K, McArthur G, Society for Melanoma Research annual meeting, 1/1/2011
• Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with docetaxel.
  D. W. Rasco, A. Patnaik, R. K. Amaravadi, K. P. Papadopoulos, N. B. Haas, A. W. Tolcher, M. Beeram, K. Harlacker, M. A. Drouin, M. Tawashi, J. Wang, A. Karam, C. R. Ma..., Journal of Clinical Oncology, 1/1/2011
• Combined mTOR inhibition and autophagy inhibition: Phase I trial of temsirolimus and hydroxchloroquine in patients with advanced solid tumors.
  Kenneth M. Algazy, Lynn M. Schuchter, Angela M. Demichele, Vaughn J. David, Drew A. Torigian, Claire Y. Chang, Maryann Redlinger, Lisa E. Davis, Peter J. O'Dwyer, Ravi..., Proceedings of the American Association for Cancer Research Annual Meeting, 1/1/2011
• Combining chemotherapy with autophagy inhibition: Phase I trial of dose-intense temozolomide and hydroxchloroquine in patients with advanced solid tumors
  Leslie A. Fecher, Lynn M. Schuchter, Tracey Evans, Claire Y. Chang, Maryann Gallagher, Amy Kramer, Peter J. O'Dwyer, Ravi K. Amaravadi, Proceedings of the American Association for Cancer Research annual meeting, 1/1/2011
• Pharmacokinetic analysis and pharmacodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloro...
  M. R. Rosenfeld, S. A. Grossman, S. Brem, T. Mikkelsen, D. Wang, S. Piao, L. E. Davis, P. J. O'Dwyer, R. K. Amaravadi, Journal of Clinical Oncology, 1/1/2010
• Autophagy can contribute to cell death when combining targeted therapy.
  Amaravadi, RK, Cancer Biology and Therapy, 1/1/2009
• Join now to see all

Lectures

• Targeting Autophagy in Cancer 
  University of Arizona Cancer Center, Tucson, AZ - 1/1/2015
• Advances in Melanoma 
  1/1/2015
• Targeted therapies for melanoma. 
  1/1/2015
• Targeted therapies for metastatic melanoma. 
  1/1/2015
• Chloroquine Derivatives as anti-cancer agents. 
  1/1/2015
• Pharmacodynamic and Pharmaockinetic studies in Phase I Clinical Trials 
  University of Pennsylvania, Philadelphia, PA - 1/1/2015
• Clinical Trials and Translational Research (EP815) 
  University of Pennsylvania, Philadelphia, PA - 1/1/2015
• Targeting the lysosome to cripple cancer cell metabolism. 
  Philadelphia, PA - 1/1/2015
• Targeting the lysosome in brain metastases. 
  Philadelphia, PA - 1/1/2015
• Targeting autophagy to improve cancer therapy. 
  Austin, TX - 1/1/2014
• Targeting autophagy in human health and disease. 
  1/1/2014
• Targeting the lysosome for cancer. 
  1/1/2014
• Autophagy as a resistance mechanism to signaling inhibitors. 
  Philadelphia, PA - 1/1/2014
• Sabotaging self preservation programs in melanoma by blocking autophagy. 
  Pennsylvania State University Melanoma Center, State College, PA - 1/1/2013
• From Bench to Bedside and Back 
  1/1/2013
• A phase 1 study of birinapant (TL32711) combined with chemotherapies demonstrates tolerability and clinical activity for solid tumor patients. 
  1/1/2013
• Credentialing response biomarkers for targeted therapies. 
  Washington, DC - 1/1/2013
• Autophagy Inhibition for Cancer Therapy 
  University of Pittsburgh, Pittsburgh, PA - 1/1/2013
• Molecular Biology of Genomics 
  Abramson Cancer Center of the University of Pennsylvania - 1/27/2012
• Targeting autophagy in cancer. 
  Berlin, Germany - 1/1/2012
• Targeting autophagy for cancer therapy. 
  Albert Einstein Cancer Center, Bronx, NY - 1/1/2012
• Developing targeted therapies for cancer. 
  1/1/2012
• Development of colonic adenomas and gastrointestinal polyps in BRAF mutant melanoma patients treated with vemurafenib. 
  1/1/2012
• Autophagy inhibition in cancer: progress and unanswered questions. 
  Vancouver, British Columbia, Canada - 1/1/2012
• Applying Lessons learned from targeting BRAF in melanoma to targeting autophagy in cancer. 
  Knight Cancer Institute, Oregon Health and Science University, Portland, OR - 1/1/2012
• Join now to see all